



## ASO Visual Abstract: FOLFIRINOX or Gemcitabine Based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-Institutional, Patient-Level Meta-Analysis and Systematic Review

Dilmurodjon Eshmuminov, MD<sup>1</sup>, Botirjon Aminjonov, MD<sup>1</sup>, Russell F. Palm, MD<sup>2</sup>, Giuseppe Malleo, MD<sup>3</sup>, Ryan K. Schmocker, MD<sup>4,5</sup>, Raëf Abdallah, MD<sup>6</sup>, Changhoon Yoo, MD<sup>7</sup>, Walid L. Shaib, MD<sup>8,9</sup>, Marcel André Schneider, MD, PhD<sup>1</sup>, Elena Rangelova, MD<sup>10,11</sup>, Yoo Jin Choi, MD<sup>12</sup>, Hongbeom Kim, MD<sup>12</sup>, J. Bart Rose, MD<sup>13</sup>, Sameer Patel, MD<sup>14</sup>, Gregory C. Wilson, MD<sup>14</sup>, Sarah Maloney, MD<sup>15</sup>, Lea Timmermann, MD<sup>16</sup>, Klaus Sahora, MD<sup>17</sup>, Fabian Rössler, MD<sup>1</sup>, Víctor Lopez-Lopez, MD<sup>18</sup>, Emanuel Boyer, MD<sup>19</sup>, Laura Maggino, MD<sup>3</sup>, Thomas Malinka, MD<sup>16</sup>, Jeong Youp Park, MD<sup>20</sup>, Matthew H. G. Katz, MD<sup>21</sup>, Laura Prakash, MD<sup>21</sup>, Syed A. Ahmad, MD<sup>14</sup>, Scott Helton, MD<sup>22</sup>, Jin-Young Jang, MD<sup>12</sup>, Sarah E. Hoffe, MD<sup>2</sup>, Roberto Salvia, MD<sup>3</sup>, Julien Taieb, MD<sup>6</sup>, Jin He, MD<sup>4</sup>, Pierre-Alain Clavien, MD, PhD<sup>1</sup>, Ulrike Held, PhD<sup>23</sup>, and Kuno Lehmann, MD, PhD<sup>1</sup>

<sup>1</sup>Department of Surgery and Transplantation, University Hospital Zurich and University of Zurich, Zurich, Switzerland; <sup>2</sup>Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; <sup>3</sup>Unit of General and Pancreatic Surgery, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Verona, Italy; <sup>4</sup>Department of Surgery, The Division of Hepatobiliary and Pancreatic Surgery, Johns Hopkins Hospital, Baltimore, MD; <sup>5</sup>Department of Surgery, University of Tennessee Graduate School of Medicine, Knoxville, TN; <sup>6</sup>Hepatogastroenterology and gastrointestinal oncology department, hôpital Européen Georges-Pompidou, AGEO (Association des Gastro-Enterologues Oncologues), Université de Paris, SIRIC CARPEM, Paris, France; <sup>7</sup>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; <sup>8</sup>Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta; <sup>9</sup>Emory University School of Medicine, Atlanta, GA; <sup>10</sup>Department of Upper Gastrointestinal Diseases, Karolinska University Hospital and Department of Clinical Science, Intervention, and Technology (CLINTEC) at Karolinska Institute, Stockholm, Sweden; <sup>11</sup>Department of Surgery, The Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; <sup>12</sup>Department of Surgery, Seoul National University, Seoul National University College of Medicine, Seoul, Korea; <sup>13</sup>Division of Surgical Oncology, Pancreatobiliary Disease Center at UAB, The University of Alabama at Birmingham, Birmingham, AL; <sup>14</sup>Division of Surgical Oncology, Department of Surgery, University of Cincinnati, Cincinnati, OH; <sup>15</sup>Department of Oncology, Royal North Shore Hospital, Sydney, NSW, Australia; <sup>16</sup>Department of Surgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; <sup>17</sup>Departments of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; <sup>18</sup>Department of General, Visceral and Transplantation Surgery, Clinic and University Hospital Virgen de la Arrixaca, IMIB-ARRIXACA, Murcia, Spain; <sup>19</sup>University of South Florida School of Medicine, Tampa, FL; <sup>20</sup>Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; <sup>21</sup>University of Texas MD Anderson Cancer Center, Houston, TX; <sup>22</sup>Section

Dilmurodjon Eshmuminov, Botirjon Aminjonov and Russell F. Palm share first authorship.

© Society of Surgical Oncology 2023


Published online: 17 April 2023

K. Lehmann, MD, PhD  
e-mail: kuno.lehmann@usz.ch

of General, Thoracic and Vascular Surgery, Department of Surgery, Virginia Mason Medical Center, Seattle, WA; <sup>23</sup>Department of Biostatistics at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

We performed a systematic review and multi-institutional meta-analysis of patient-level data regarding the use of initial systemic therapy for BRPC and LAPC (<https://doi.org/10.1245/s10434-023-13353-2>).

Outcomes were reported separately for tumor entity and by chemotherapy regimen, including FOLFIRINOX (FIO) or gemcitabine-based. In patients with BRPC or LAPC, primary treatment with FOLFIRINOX compared with gemcitabine-based chemotherapy appears to provide a survival benefit for patients who are ultimately unresectable. For patients that undergo surgical resection, outcomes are similar between GEM+ and FOLFIRINOX when delivered in the neoadjuvant setting.



**FUNDING** None.

**DISCLOSURE** Sarah Hoffe: Galera Pharmaceuticals, Institutional Principal Investigator for the GRECO-2 randomized international study for which my cancer center receives funding to support the trial, it is a pancreas trial that includes SBRT.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.